IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#860
Positioning
Market Dominance
Manufacturing
Machinery
$13M
Steven Sherman
Ekso Bionics Holdings, Inc. designs, develops, sells, rents, and rents exoskeleton products. EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury. The company has a license agreement with Lockheed Martin Corporation.
Headcount
60
HQ Base
RICHMOND, California
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EKSO EKSO BIONICS HOLDINGS, INC. | 58 | 49 | 30 | 97 | - | - | -94.0% | -42.0% | 51.8% | -98.1% | -75.3% | -14.6% | 0.0% | 124.0x | $13M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
EKSO BIONICS HOLDINGS, INC. (EKSO) receives a "Hold" rating with a composite score of 58.3/100. It ranks #860 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for EKSO.
View All RatingsROIC -72.2% vs WACC 8.8% (spread -81.0%)
GM 52% vs sector 44%, OM -98% vs sector 3%
Capital turnover 2.75x, R&D intensity 24.7%
Rev growth -15%, 10yr history
Interest coverage -77.9x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate EKSO BIONICS HOLDINGS, INC. (EKSO) as a Hold with a composite score of 58.3/100 at a current price of $10.17. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
EKSO BIONICS HOLDINGS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 58.3/100 places it at rank #860 in our full universe.
The near-term outlook is constructive, with revenue growing at -15% and momentum in the 97th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
Very High
Poor
Fair Value
Gross margins of 52% signal strong pricing power.
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Leverage of 124% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
EKSO BIONICS HOLDINGS, INC. represents a hold based on multi-factor quantitative performance.
Our model assigns EKSO BIONICS HOLDINGS, INC. a Hold rating, with a composite score of 58.3/100 and 3 out of 5 stars. Ranked #860 of 7,333 stocks, EKSO presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 49/100, EKSO shows adequate but unremarkable business quality. The company reports a return on equity of -94.0% (sector avg: -1.9%), gross margins of 51.8% (sector avg: 44.1%), net margins of -75.3% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 30/100, EKSO appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 4.12x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
EKSO BIONICS HOLDINGS, INC.'s investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -14.6% vs. a sector average of 6.7% and a return on assets of -42.0% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
EKSO BIONICS HOLDINGS, INC. (EKSO) is exhibiting exceptional momentum with a score of 97/100, placing it among the strongest trending stocks in the market. Revenue growth stands at -14.6% year-over-year, while a beta of 3.10 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting EKSO may continue to benefit from strong institutional interest and positive price trends.
EKSO BIONICS HOLDINGS, INC. registers a low stability score of 12/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 3.10 and a debt-to-equity ratio of 124.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
EKSO's short interest factor score of 86/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include high market sensitivity (beta: 3.10), elevated leverage (D/E: 124.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $13M, EKSO BIONICS HOLDINGS, INC. benefits from the generally lower volatility and deeper liquidity associated with its size class.
EKSO BIONICS HOLDINGS, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #860 of 7,333 overall (88th percentile). Key comparisons include ROE of -94.0% trailing the -1.9% sector median and operating margins of -98.1% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While EKSO currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (97) vs Stability (12) — closing this gap could shift the rating.
ROE 4845% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 18% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 4007% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
H.C. Wainwright downgraded Ekso Bionics (EKSO) to Neutral from Buy after the company announced a non-binding merger agreement with Applied Digital Cloud (APLD). The firm deemed the transaction prudent given the current financial environment but noted Ekso is moving away from its core business of commercializing exoskeletons. This shift led to the downgrade, as the company's focus is no longer exclusively on its original specialization.
Ekso Bionics announced a stock-for-stock business combination with Applied Digital Cloud, involving the issuance of 138.2 million new shares and a planned rebranding to ChronoScale. The deal will result in the contributor owning approximately 97% of the combined company, subject to stockholder approval and other conditions. Additionally, an Investor Rights Agreement will grant APLD investors scaled board designation and other rights, aligning governance with the new ownership structure.
H.C. Wainwright has downgraded Ekso Bionics (NASDAQ:EKSO) from Buy to Neutral after the announcement of its proposed merger with Applied Digital Cloud. The downgrade reflects Ekso Bionics' shift away from its core exoskeleton business, despite the stock's recent significant gains. Upon completion of the merger, the combined entity will be renamed ChronoScale Corporation, with EKSO shareholders receiving a 3% equity stake.
This page provides live stock quotes and charts for Ekso Bionics Holdings Inc. (EKSO). As of the article's time, EKSO stock is trading at $8.65, down 18.24%. The page also offers information on earnings, analyst ratings, and includes a promotional offer for a trading bootcamp.
Applied Digital Corp. plans to spin out its cloud computing business and merge it with a California-based powered exoskeleton company. The Dallas-based company, led by CEO Wes Cummins, has struck a deal with EKSO Bionics to create ChronoScale. This strategic move aims to combine cloud computing capabilities with robotics for a unique venture.